Evidence map›Paper›PMID 31927793›Full record

ArticleHIV medicine2020

Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation.

O T Stirrup, D Asboe, A Pozniak, C A Sabin, R Gilson, N E Mackie, A Tostevin, T Hill, D T Dunn, UK HIV Drug Resistance Database and the UK Collaborative HIV Cohort

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in HIV medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Acute HIV Diagnosis After Initiation of Pre-exposure Prophylaxis in a Young Adult Patient: A Case Report.The Journal of adolescent health : official publication of the Society for Adolescent Medicine · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

O T StirrupInstitute for Global Health, University College London, London, UK.ORCID 0000-0002-8705-3281
D AsboeChelsea and Westminster Hospital, London, UK.
A PozniakChelsea and Westminster Hospital, London, UK.
C A SabinInstitute for Global Health, University College London, London, UK.ORCID 0000-0001-5173-2760
R GilsonInstitute for Global Health, University College London, London, UK.
N E MackieImperial College Healthcare NHS Trust, London, UK.
A TostevinInstitute for Global Health, University College London, London, UK.
T HillInstitute for Global Health, University College London, London, UK.
D T DunnInstitute for Global Health, University College London, London, UK.
UK HIV Drug Resistance Database and the UK Collaborative HIV Cohort
University College London · GBChelsea and Westminster Hospital · GBImperial College Healthcare NHS Trust · GBLondon School of Hygiene & Tropical Medicine · GBMortimer Market Centre · GB

Funding

Medical Research Council 164587Medical Research Council MR/M004236/1
6 · The paper itself

Abstract

objectivesThe aim of the study was to investigate whether lamivudine (3TC) or emtricitabine (FTC) use following detection of M184V/I is associated with better virological outcomes.

methodsWe identified people with viruses harbouring the M184V/I mutation in UK multicentre data sets who had treatment change/initiation within 1 year. We analysed outcomes of viral suppression (< 200 HIV-1 RNA copies/mL) and appearance of new major drug resistance mutations (DRMs) using Cox and Poisson models, with stratification by new drug regimen (excluding 3TC/FTC) and Bayesian implementation, and estimated the effect of 3TC/FTC adjusted for individual and viral characteristics.

resultsWe included 2597 people with the M184V/I resistance mutation, of whom 665 (25.6%) were on 3TC and 458 (17.6%) on FTC. We found a negative adjusted association between 3TC/FTC use and viral suppression [hazard ratio (HR) 0.84; 95% credibility interval (CrI) 0.71-0.98]. On subgroup analysis of individual drugs, there was no evidence of an association with viral suppression for 3TC (n = 184; HR 0.94; 95% CrI 0.73-1.15) or FTC (n = 454; HR 0.99; 95% CrI 0.80-1.19) amongst those on tenofovir-containing regimens, but we estimated a reduced rate of viral suppression for people on 3TC amongst those without tenofovir use (n = 481; HR 0.71; 95% CrI 0.54-0.90). We found no association between 3TC/FTC and detection of any new DRM (overall HR 0.92; 95% CrI 0.64-1.18), but found inconclusive evidence of a lower incidence rate of new DRMs (overall incidence rate ratio 0.69; 95% CrI 0.34-1.11).

conclusionsWe did not find evidence that 3TC or FTC use is associated with an increase in viral suppression, but it may reduce the appearance of additional DRMs in people with M184V/I. 3TC was associated with reduced viral suppression amongst people on regimens without tenofovir.

Indexed as

AdultAnti-HIV AgentsDrug Resistance, ViralDrug Therapy, CombinationEmtricitabineFemaleHIV-1HIV InfectionsHumansLamivudineMaleMutationTenofovirTreatment FailureUnited KingdomAnti-HIV AgentsEmtricitabineLamivudineTenofoviremtricitabineHIVlamivudineM184IM184V

Identifiers

PMID31927793
PMCPMC7217157
OpenAlexW2998952559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.